<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782795</url>
  </required_header>
  <id_info>
    <org_study_id>CP-PENQEX-1R21AA017271</org_study_id>
    <secondary_id>R21AA017271</secondary_id>
    <secondary_id>1R21AA017271-01A1</secondary_id>
    <nct_id>NCT00782795</nct_id>
  </id_info>
  <brief_title>Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function &amp; Structure, Pain &amp; Life Quality</brief_title>
  <official_title>Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function &amp; Structure, Pain &amp; Life Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if study drug (Pioglitazone) treatment will improve
      pre-diabetes (insulin resistance) or ealy diabetes and improve clinical symptoms (pain) or
      laboratory evidence of chronic pancreatitis.

      The goal of the investigators is to gather information from this study to help gain
      understanding of a potential therapy for chronic pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pancreas is a digestive organ that secretes insulin (and other hormones) into the blood
      for regulating blood sugar (glucose) and digestive enzymes into the intestine for digesting
      and absorbing nutrients consumed in meals. Chronic pancreatitis is a progressive clinical
      disease of the pancreas, associated with swelling (inflammation), scarring (fibrosis) and
      loss of normal functioning tissue. Patients develop diabetes mellitus (elevated blood sugar),
      malabsorption of nutrients, weight loss and pain. Presently chronic pancreatitis is
      considered an irreversible condition because the mechanisms responsible for chronic
      pancreatitis are poorly understood and no therapy is proven. However, recent studies provide
      important clues that oral medications (Thiazolidinediones) used to treat diabetes mellitus
      might improve or reverse features of chronic pancreatitis, including elevated sugar or
      diabetes, reduced secretion of digestive enzymes, and pancreatic swelling and scarring.

      Note: Takeda Pharmaceuticals North America (TPNA) provided pioglitazone and placebo pills
      with identically appearance until June 28, 2010, approximately the middle of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose Tolerance at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Normal = normal plasma glucose and normal glucose tolerance (OGTT).
Impaired category includes all non-diabetic participants with either a) Impaired fasting glucose = fasting plasma glucose &gt;110 mg/dl and &lt;126 mg/dl; or b) Impaired glucose intolerance = 2-hour plasma glucose (OGTT) &gt;140 mg/dl and &lt;200 mg/dl.
Diabetes = fasting plasma glucose &gt;126 mg/dl 2-hour (OGTT) plasma glucose &gt;200 mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Tolerance at 48 Weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>Normal = normal plasma glucose and normal glucose tolerance (OGTT).
Impaired category includes all non-diabetic participants with either a) Impaired fasting glucose = fasting plasma glucose &gt;110 mg/dl and &lt;126 mg/dl; or b) Impaired glucose intolerance = 2-hour plasma glucose (OGTT) &gt;140 mg/dl and &lt;200 mg/dl.
Diabetes = fasting plasma glucose &gt;126 mg/dl 2-hour (OGTT) plasma glucose &gt;200 mg/dl.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity Index for Glycemia at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Insulin Sensitivity = Index for Glycemia (ISI gly) = 2 / ([INSp x GLYp] + 1).
GLYp = Glycemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr glucose.
INSp = Insulinemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr insulin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity Index for Glycemia at 48 Weeks.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Insulin Sensitivity = Index for Glycemia (ISI gly) = 2 / ([INSp x GLYp] + 1).
GLYp = Glycemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr glucose.
INSp = Insulinemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr insulin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-cell Function</measure>
    <time_frame>24, 48 weeks</time_frame>
    <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance at 24 and 48 Weeks</measure>
    <time_frame>24, 48 weeks</time_frame>
    <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pancreas Ultrasound Appearance</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean score on a scale of 0 - 10: count of positive Endoscopic Ultrasound(EUS) features:
Parenchymal Features - Only Body and Tail
Calcification (&gt;3 hyperechoic foci &gt;2 mm length &amp; width with shadowing)
Lobularity (&gt;3 well-circumscribed, &gt;5mm structures)
Hyperechoic stranding (&gt;3 hyperechoic lines &gt;3mm in length, seen in &gt; 2 different directions with respect to the imaged plane Parenchymal Features - Head, Body and Tail
Cyst (&gt;2 mm diameter anechoic round or oval structure)
Hyperechoic foci (&gt;3 reflectors, &gt;3 mm long &amp; wide, no shadowing) Ductal Features - Only Body and Tail
Side Branch Dilation (&gt;3 tubular, anechoic, &gt;1 mm structures,Main pancreatic duct (MPD) connects)
Irregular MPD contour (uneven and ectatic in its course)
Hyperechoic MPD margin (hyperechoic in &gt;50% of MPD)
Dilation MPD (&gt;3.5 mm body, &gt;1.5 mm tail*) Ductal Features - Head, Body and Tail
MPD calculi (hyperechoic foci with shadowing contained within MPD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>24, 48 weeks</time_frame>
    <description>The SF36 (Short Form with 36 questions) QoL scoring system has 36 questions, comprising two main dimensions (Physical Health and Mental Health), further divided by 8 independent scales (Physical functioning, Role-Physical, Bodily pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health). The scales for general health and mental health overlap components of both the two main dimensions (Physical Health and Mental Health). The scales, including the total score and dimensions are scored as a number between 0 and 100, where 0 represents lower limits of functioning and 100 is best functioning possible. Data reported is the average total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and Percentage of Participants With Steatorrhea</measure>
    <time_frame>48 weeks</time_frame>
    <description>Participants were counted as having steatorrhea if they had either a) positive qualitative fecal fat; or b) 72 hour quantitative fecal fat result with &gt;7g fat in stool in 24hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>12, 24, 36, 48 and 60 weeks</time_frame>
    <description>Pain is reported as the mean of four Visual analogue scales, ranging from 0 points (no pain) to 100 points (severe pain)
What is your pain right now?
What is your typical or average pain in the last 12 weeks?
What is your pain level at its best in the last 12 weeks (how close to &quot;0&quot; does your pain get at its best)?
What is your pain level at its worst in the last 12 weeks (how close to &quot;0&quot; does your pain get at its worst)?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>12, 24, 36, 48 and 60 weeks</time_frame>
    <description>standard BMI defined as mass in kilograms divided by height in meters squared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>12, 24, 36, 48 and 60 weeks</time_frame>
    <description>Mean number of hospitalizations within the prior 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Missed Work</measure>
    <time_frame>12, 24, 36, 48, 60 weeks</time_frame>
    <description>Mean days of missed work reported by participants in response to question asking about missed work since the last visit (12 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity (%S)</measure>
    <time_frame>24 and 48 weeks</time_frame>
    <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Chronic Pancreatitis</condition>
  <condition>Insulin Resistance</condition>
  <condition>Normal or Mildly Abnormal Stool Fat Levels</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 sugar pill (placebo) taken once daily for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Participants randomized to pioglitazone receive 30 mg taken once daily for 48 weeks.</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>sugar pill (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insulin resistance or mild diabetes mellitus

          -  Symptoms of abdominal pain

          -  Xray test showing damage to the pancreas

          -  Normal or mildly abnormal stool fat levels

        Exclusion Criteria:

          -  Mentally disabled patients

          -  Women who are planning pregnancy, pregnant or lactating/nursing

          -  Chronic pancreatitis is due to other specific conditions

               -  Autosomal dominant pancreatitis

               -  Classic cystic fibrosis with lung involvement

               -  Autoimmune pancreatitis

               -  Pancreatic cancer

               -  Biliary obstruction (non-pancreatic cause)

               -  Abdominal trauma

               -  Hypercalcemia

               -  Hypertriglyceridemia

          -  Surgical resection of the head of the pancreas

          -  Alcohol consumption within prior 2 months

          -  Specific medical conditions

               -  Gastric surgery

               -  Celiac sprue

               -  Crohns disease

               -  Heart failure

               -  Kidney failure

               -  Cirrhosis or liver disease

               -  Osteoporosis

               -  Blood clotting disorder

               -  Visual problems

               -  Low albumin

               -  Low BMI

          -  Specific medications *Diabetes drug treatment is allowed except for short-acting
             insulin, long-acting insule more than 15 units daily, pioglitazone, rosiglitazone,
             orlistat, acarbose, miglitol or voglibose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew DiMagno, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>September 19, 2017</results_first_submitted>
  <results_first_submitted_qc>November 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Matthew DiMagno, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Chronic pancreatitis</keyword>
  <keyword>Insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>39 screen fails did not go on to randomization</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pioglitazone</title>
          <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill (Placebo)</title>
          <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Weeks (1st Apptment)</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>24 Week Appointment</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pioglitazone</title>
          <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill (Placebo)</title>
          <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.35" spread="7.61"/>
                    <measurement group_id="B2" value="48.37" spread="9.83"/>
                    <measurement group_id="B3" value="51.08" spread="8.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose Tolerance at 24 Weeks</title>
        <description>Normal = normal plasma glucose and normal glucose tolerance (OGTT).
Impaired category includes all non-diabetic participants with either a) Impaired fasting glucose = fasting plasma glucose &gt;110 mg/dl and &lt;126 mg/dl; or b) Impaired glucose intolerance = 2-hour plasma glucose (OGTT) &gt;140 mg/dl and &lt;200 mg/dl.
Diabetes = fasting plasma glucose &gt;126 mg/dl 2-hour (OGTT) plasma glucose &gt;200 mg/dl.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tolerance at 24 Weeks</title>
          <description>Normal = normal plasma glucose and normal glucose tolerance (OGTT).
Impaired category includes all non-diabetic participants with either a) Impaired fasting glucose = fasting plasma glucose &gt;110 mg/dl and &lt;126 mg/dl; or b) Impaired glucose intolerance = 2-hour plasma glucose (OGTT) &gt;140 mg/dl and &lt;200 mg/dl.
Diabetes = fasting plasma glucose &gt;126 mg/dl 2-hour (OGTT) plasma glucose &gt;200 mg/dl.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired Glucose Tolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Tolerance at 48 Weeks</title>
        <description>Normal = normal plasma glucose and normal glucose tolerance (OGTT).
Impaired category includes all non-diabetic participants with either a) Impaired fasting glucose = fasting plasma glucose &gt;110 mg/dl and &lt;126 mg/dl; or b) Impaired glucose intolerance = 2-hour plasma glucose (OGTT) &gt;140 mg/dl and &lt;200 mg/dl.
Diabetes = fasting plasma glucose &gt;126 mg/dl 2-hour (OGTT) plasma glucose &gt;200 mg/dl.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Tolerance at 48 Weeks</title>
          <description>Normal = normal plasma glucose and normal glucose tolerance (OGTT).
Impaired category includes all non-diabetic participants with either a) Impaired fasting glucose = fasting plasma glucose &gt;110 mg/dl and &lt;126 mg/dl; or b) Impaired glucose intolerance = 2-hour plasma glucose (OGTT) &gt;140 mg/dl and &lt;200 mg/dl.
Diabetes = fasting plasma glucose &gt;126 mg/dl 2-hour (OGTT) plasma glucose &gt;200 mg/dl.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Impaired Glucose Tolerance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity Index for Glycemia at 24 Weeks</title>
        <description>Insulin Sensitivity = Index for Glycemia (ISI gly) = 2 / ([INSp x GLYp] + 1).
GLYp = Glycemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr glucose.
INSp = Insulinemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr insulin.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity Index for Glycemia at 24 Weeks</title>
          <description>Insulin Sensitivity = Index for Glycemia (ISI gly) = 2 / ([INSp x GLYp] + 1).
GLYp = Glycemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr glucose.
INSp = Insulinemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr insulin.</description>
          <units>numeric index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.11"/>
                    <measurement group_id="O2" value="0.35" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity Index for Glycemia at 48 Weeks.</title>
        <description>Insulin Sensitivity = Index for Glycemia (ISI gly) = 2 / ([INSp x GLYp] + 1).
GLYp = Glycemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr glucose.
INSp = Insulinemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr insulin.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity Index for Glycemia at 48 Weeks.</title>
          <description>Insulin Sensitivity = Index for Glycemia (ISI gly) = 2 / ([INSp x GLYp] + 1).
GLYp = Glycemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr glucose.
INSp = Insulinemic 0-2 hr area = sum of normalized (based on institutional values) 0 &amp; 2 hr insulin.</description>
          <units>numeric index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.13"/>
                    <measurement group_id="O2" value="0.36" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Beta-cell Function</title>
        <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/</description>
        <time_frame>24, 48 weeks</time_frame>
        <population>1 participant on the placebo side was no longer participating at 48 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Beta-cell Function</title>
          <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/</description>
          <population>1 participant on the placebo side was no longer participating at 48 weeks</population>
          <units>Beta-cell function (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110.51" spread="31.59"/>
                    <measurement group_id="O2" value="120.59" spread="48.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.60" spread="61.53"/>
                    <measurement group_id="O2" value="120.68" spread="44.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Resistance at 24 and 48 Weeks</title>
        <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/</description>
        <time_frame>24, 48 weeks</time_frame>
        <population>1 participant on the placebo side was no longer participating at 48 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Resistance at 24 and 48 Weeks</title>
          <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/</description>
          <population>1 participant on the placebo side was no longer participating at 48 weeks</population>
          <units>HOMA2-IR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="1.29"/>
                    <measurement group_id="O2" value="2.27" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.85"/>
                    <measurement group_id="O2" value="2.42" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pancreas Ultrasound Appearance</title>
        <description>Mean score on a scale of 0 - 10: count of positive Endoscopic Ultrasound(EUS) features:
Parenchymal Features - Only Body and Tail
Calcification (&gt;3 hyperechoic foci &gt;2 mm length &amp; width with shadowing)
Lobularity (&gt;3 well-circumscribed, &gt;5mm structures)
Hyperechoic stranding (&gt;3 hyperechoic lines &gt;3mm in length, seen in &gt; 2 different directions with respect to the imaged plane Parenchymal Features - Head, Body and Tail
Cyst (&gt;2 mm diameter anechoic round or oval structure)
Hyperechoic foci (&gt;3 reflectors, &gt;3 mm long &amp; wide, no shadowing) Ductal Features - Only Body and Tail
Side Branch Dilation (&gt;3 tubular, anechoic, &gt;1 mm structures,Main pancreatic duct (MPD) connects)
Irregular MPD contour (uneven and ectatic in its course)
Hyperechoic MPD margin (hyperechoic in &gt;50% of MPD)
Dilation MPD (&gt;3.5 mm body, &gt;1.5 mm tail*) Ductal Features - Head, Body and Tail
MPD calculi (hyperechoic foci with shadowing contained within MPD)</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pancreas Ultrasound Appearance</title>
          <description>Mean score on a scale of 0 - 10: count of positive Endoscopic Ultrasound(EUS) features:
Parenchymal Features - Only Body and Tail
Calcification (&gt;3 hyperechoic foci &gt;2 mm length &amp; width with shadowing)
Lobularity (&gt;3 well-circumscribed, &gt;5mm structures)
Hyperechoic stranding (&gt;3 hyperechoic lines &gt;3mm in length, seen in &gt; 2 different directions with respect to the imaged plane Parenchymal Features - Head, Body and Tail
Cyst (&gt;2 mm diameter anechoic round or oval structure)
Hyperechoic foci (&gt;3 reflectors, &gt;3 mm long &amp; wide, no shadowing) Ductal Features - Only Body and Tail
Side Branch Dilation (&gt;3 tubular, anechoic, &gt;1 mm structures,Main pancreatic duct (MPD) connects)
Irregular MPD contour (uneven and ectatic in its course)
Hyperechoic MPD margin (hyperechoic in &gt;50% of MPD)
Dilation MPD (&gt;3.5 mm body, &gt;1.5 mm tail*) Ductal Features - Head, Body and Tail
MPD calculi (hyperechoic foci with shadowing contained within MPD)</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="4" upper_limit="5"/>
                    <measurement group_id="O2" value="4.91" lower_limit="3.5" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life</title>
        <description>The SF36 (Short Form with 36 questions) QoL scoring system has 36 questions, comprising two main dimensions (Physical Health and Mental Health), further divided by 8 independent scales (Physical functioning, Role-Physical, Bodily pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health). The scales for general health and mental health overlap components of both the two main dimensions (Physical Health and Mental Health). The scales, including the total score and dimensions are scored as a number between 0 and 100, where 0 represents lower limits of functioning and 100 is best functioning possible. Data reported is the average total score.</description>
        <time_frame>24, 48 weeks</time_frame>
        <population>The 24 week data has two participants' data missing from each arm because it was not available.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life</title>
          <description>The SF36 (Short Form with 36 questions) QoL scoring system has 36 questions, comprising two main dimensions (Physical Health and Mental Health), further divided by 8 independent scales (Physical functioning, Role-Physical, Bodily pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health). The scales for general health and mental health overlap components of both the two main dimensions (Physical Health and Mental Health). The scales, including the total score and dimensions are scored as a number between 0 and 100, where 0 represents lower limits of functioning and 100 is best functioning possible. Data reported is the average total score.</description>
          <population>The 24 week data has two participants' data missing from each arm because it was not available.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.74" spread="29.13"/>
                    <measurement group_id="O2" value="70.06" spread="18.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" spread="26.33"/>
                    <measurement group_id="O2" value="64.71" spread="23.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percentage of Participants With Steatorrhea</title>
        <description>Participants were counted as having steatorrhea if they had either a) positive qualitative fecal fat; or b) 72 hour quantitative fecal fat result with &gt;7g fat in stool in 24hours</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With Steatorrhea</title>
          <description>Participants were counted as having steatorrhea if they had either a) positive qualitative fecal fat; or b) 72 hour quantitative fecal fat result with &gt;7g fat in stool in 24hours</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Pain is reported as the mean of four Visual analogue scales, ranging from 0 points (no pain) to 100 points (severe pain)
What is your pain right now?
What is your typical or average pain in the last 12 weeks?
What is your pain level at its best in the last 12 weeks (how close to 0 does your pain get at its best)?
What is your pain level at its worst in the last 12 weeks (how close to 0 does your pain get at its worst)?</description>
        <time_frame>12, 24, 36, 48 and 60 weeks</time_frame>
        <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Pain is reported as the mean of four Visual analogue scales, ranging from 0 points (no pain) to 100 points (severe pain)
What is your pain right now?
What is your typical or average pain in the last 12 weeks?
What is your pain level at its best in the last 12 weeks (how close to 0 does your pain get at its best)?
What is your pain level at its worst in the last 12 weeks (how close to 0 does your pain get at its worst)?</description>
          <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" spread="21.46"/>
                    <measurement group_id="O2" value="23.03" spread="25.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.32" spread="28.84"/>
                    <measurement group_id="O2" value="18.92" spread="22.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.88" spread="21.97"/>
                    <measurement group_id="O2" value="23.55" spread="23.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.42" spread="26.52"/>
                    <measurement group_id="O2" value="27.50" spread="27.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.15" spread="16.08"/>
                    <measurement group_id="O2" value="26.11" spread="24.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI)</title>
        <description>standard BMI defined as mass in kilograms divided by height in meters squared</description>
        <time_frame>12, 24, 36, 48 and 60 weeks</time_frame>
        <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>standard BMI defined as mass in kilograms divided by height in meters squared</description>
          <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.02" spread="5.73"/>
                    <measurement group_id="O2" value="28.64" spread="6.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.56" spread="4.46"/>
                    <measurement group_id="O2" value="29.49" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.55" spread="5.92"/>
                    <measurement group_id="O2" value="27.46" spread="6.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.26" spread="6.36"/>
                    <measurement group_id="O2" value="28.75" spread="6.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.20" spread="4.36"/>
                    <measurement group_id="O2" value="27.94" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations</title>
        <description>Mean number of hospitalizations within the prior 12 weeks</description>
        <time_frame>12, 24, 36, 48 and 60 weeks</time_frame>
        <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations</title>
          <description>Mean number of hospitalizations within the prior 12 weeks</description>
          <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="1.13"/>
                    <measurement group_id="O2" value="0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.45"/>
                    <measurement group_id="O2" value="0.07" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.12" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Missed Work</title>
        <description>Mean days of missed work reported by participants in response to question asking about missed work since the last visit (12 weeks)</description>
        <time_frame>12, 24, 36, 48, 60 weeks</time_frame>
        <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Missed Work</title>
          <description>Mean days of missed work reported by participants in response to question asking about missed work since the last visit (12 weeks)</description>
          <population>Some participant data is missing from some weeks, due to incomplete forms in certain instances.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="1.20"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="1.89"/>
                    <measurement group_id="O2" value="0.75" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.45"/>
                    <measurement group_id="O2" value="0.47" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.5" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0.25" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity (%S)</title>
        <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/;</description>
        <time_frame>24 and 48 weeks</time_frame>
        <population>1 participant on the placebo side was no longer participating at 48 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>Sugar Pill (Placebo)</title>
            <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Pioglitazone</title>
            <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (%S)</title>
          <description>Homeostasis model assessment (HOMA 2) values generated using calculator at https://www.dtu.ox.ac.uk/homacalculator/;</description>
          <population>1 participant on the placebo side was no longer participating at 48 weeks</population>
          <units>insulin sensitivity (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.39" spread="17.26"/>
                    <measurement group_id="O2" value="51.83" spread="20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.12" spread="17.21"/>
                    <measurement group_id="O2" value="46.18" spread="26.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <desc>All adverse events that participants raised to study team as such, all of which were reported on to the IRB, are shown below.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pioglitazone</title>
          <description>30 mg pioglitazone (Actos) tablet taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill (Placebo)</title>
          <description>1 sugar pill (placebo) taken once daily for 48 weeks.
Pioglitazone: Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>chronic vertigo exacerbation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Trauma to head</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>non-specific neck swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Matthew DiMagno</name_or_title>
      <organization>University of Michigan</organization>
      <email>mdimagno@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

